Hawkins Inc (HWKN) · Oct 26, 2026 · Earnings

Hawkins earnings beat as Water Treatment growth accelerates

Beat — Diluted EPS $1.34 vs ~$1.19 consensus; revenue $313.8M vs ~$302.7M

Hawkins earnings beat revenue and EPS expectations, led by organic Water Treatment growth, while acquisitions expand its footprint and leverage falls.

Hawkins is deepening its shift from bulk chemical distribution toward a broader specialty-ingredients and water-treatment platform. Water Treatment is the strategic growth engine, while acquisitions are being used to expand geographic reach and customer capabilities.

MetricFiscal 2027 Q2Prior-year Q2External expectation
Revenue$313.8M (Financial Statements)$280.4M~$302.7M
Diluted EPS$1.34 (Financial Statements)$1.08~$1.19
Adjusted EBITDA$59.1M (Adjusted EBITDA)$50.9M—
Gross margin24% (Financial Statements)24%—
Six-month free cash flow$53.1M (Free Cash Flow Reconciliation)$46.7M—
Debt$229.0M (Balance Sheet)$244.0M at fiscal year-end—

The quarter was a clear earnings beat, not just a favorable comparison with last year. Revenue exceeded the published consensus by roughly 4%, while diluted EPS was about 13% above expectations. The outperformance was broad: all three segments grew, and the company reported 11% organic sales growth. 〔0〕

Water Treatment is delivering the part of the strategy investors most need to see working. The segment grew 16% to $175.0 million, with organic growth of 14%, and its gross profit rose 20% to $51.7 million at a 30% margin. That makes the quarter more than an acquisition-led top-line result: core volume growth and stronger per-unit margins drove the main growth engine, although about $3.7 million of revenue came from acquired businesses. (Segment results — Water Treatment)

The beat came with a modest quality caveat: consolidated margins held flat rather than expanded. Gross profit rose 13%, but the overall margin remained 24% because higher raw-material and fuel costs, plus unfavorable LIFO effects, absorbed some of the benefit. Food & Health Sciences was the weak spot, with gross profit down 4% and margin falling to 19% despite 5% sales growth. (Segment results — Food & Health Sciences; Financial Statements)

Cash generation and balance-sheet capacity improved while Hawkins continued investing. Six-month free cash flow increased 14% to $53.1 million, funding $18.6 million of repurchases, $15.0 million of debt reduction, and $8.1 million of dividends. Debt fell to $229.0 million and leverage declined to 1.22x trailing adjusted EBITDA, giving the acquisition strategy more financial room.

The next phase is still acquisition-led, but the filing does not raise formal full-year guidance. Hawkins closed the Florida water-distribution tuck-in and subsequently added Eagle Labs and two Dallas–Fort Worth locations, extending its Water Treatment footprint. Management expects second-half trends to resemble the first half, but it also flags a $6.2 million prior-year SG&A benefit that will not repeat, which could make the second-half comparison less forgiving. 〔1〕

Bottom line: This materially advances Hawkins’ growth story: the core Water Treatment business is accelerating, the quarter beat expectations, and the company is funding expansion while reducing leverage. The main limitation is that margin expansion was not yet visible across the whole portfolio, especially in Food & Health Sciences.

What to watch next

Fiscal 2027 third-quarter earnings report

Original filing on SEC EDGAR

More Hawkins Inc news

Hawkins earnings beat as Water Treatment growth accelerates | HWKN Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.